Evaluation of Prognostic Factors and Survival Results in Pancreatic Carcinomas in Turkey

被引:8
作者
Canyilmaz, Emine [1 ]
Serdar, Lasif [1 ]
Uslu, Gonca Hanedan [2 ]
Soydemir, Gulsen [1 ]
Bahat, Zumrut [1 ]
Yoney, Adnan [1 ]
机构
[1] Karadeniz Tech Univ, Fac Med, Dept Radiat Oncol, Trabzon, Turkey
[2] Kanuni Res & Educ Hosp, Trabzon, Turkey
关键词
Pancreatic cancer; radiotherapy; chemotherapy; CEA; DUCTAL ADENOCARCINOMA; CURATIVE RESECTION; CANCER; CHEMOTHERAPY; GEMCITABINE; CHEMORADIOTHERAPY; 5-FLUOROURACIL; PATTERNS; THERAPY; FAILURE;
D O I
10.7314/APJCP.2013.14.11.6573
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The goal of this retrospective study was to evaluate patient characteristics, treatment modalitiesand prognostic factors in Turkish patients with pancreatic cancer. Materials and Methods: Between January 1997 and December 2012, 64 patients who presented to the Department of Radiation Oncology, Karadeniz Technical University, Faculty of Medicine with a diagnosis of pancreatic cancer were evaluated. The E/K ratio of the cases was 2.4/1 and the median age was 59.6 (32-80) years, respectively. Some 11 cases (18%) were stage 1, 21 (34.4%) were stage 2, 10 (16.4%) were stage 3, and 19 (31.1%) were metastatic. Results: The mean follow-up time was 15.7 months (0.7-117.5) and loco-regional recurrence was noted in 11 (40.7%) who underwent surgery while metastases were observed in 41 patients (66.1%). The median overall survival (OS) was 11.2 months and the 1, 3 and 5-year OS rates were 41.7%, 9.9% and 7.9% respectively. The median disease-free survival (DFS) was 5.2 month and the1, 2 and 5 year DFS were 22.6%, 7.6% and 3.8% respectively. On univariate analysis, prognostic factors affecting OS included status of the operation (p<0.001), tumor stage (p=0.008), ECOG performance status (p=0.005) and CEA level (p=0.017). On multivariate analysis, prognostic factors affecting survival included status of the operation (p=0.033) and age (p=0.023). Conclusions: In the current study, age and operation status were independent prognostic factors for overall survival with pancreatic patients. Thus, the patients early diagnosis and treatment ars essential. However, prospective studies with more patients are needed for confirmation.
引用
收藏
页码:6573 / 6578
页数:6
相关论文
共 33 条
[1]  
[Anonymous], 1985, Cancer, V56, P2563
[2]  
[Anonymous], CANC PANCREAS
[3]   Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer [J].
Bayraktar, Soley ;
Bayraktar, Ulas Darda ;
Rocha-Lima, Caio Max .
WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (06) :673-682
[4]   Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy [J].
Bernhard, J. ;
Dietrich, D. ;
Glimelius, B. ;
Hess, V. ;
Bodoky, G. ;
Scheithauer, W. ;
Herrmann, R. .
BRITISH JOURNAL OF CANCER, 2010, 103 (09) :1318-1324
[5]   Importance of performance status for treatment outcome in advanced pancreatic cancer [J].
Boeck, Stefan ;
Hinke, Axel ;
Wilkowski, Ralf ;
Heinemann, Volker .
WORLD JOURNAL OF GASTROENTEROLOGY, 2007, 13 (02) :224-227
[6]   TREATMENT AND SURVIVAL IN 13560 PATIENTS WITH PANCREATIC-CANCER, AND INCIDENCE OF THE DISEASE, IN THE WEST MIDLANDS - AN EPIDEMIOLOGIC-STUDY [J].
BRAMHALL, SR ;
ALLUM, WH ;
JONES, AG ;
ALLWOOD, A ;
CUMMINS, C ;
NEOPTOLEMOS, JP .
BRITISH JOURNAL OF SURGERY, 1995, 82 (01) :111-115
[7]   Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas [J].
Brennan, MF ;
Kattan, MW ;
Klimstra, D ;
Conlon, K .
ANNALS OF SURGERY, 2004, 240 (02) :293-298
[8]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[9]   Long-term survival after curative resection for pancreatic ductal adenocarcinoma - Clinicopathologic analysis of 5-year survivors [J].
Conlon, KC ;
Klimstra, DS ;
Brennan, MF .
ANNALS OF SURGERY, 1996, 223 (03) :273-279
[10]   PATTERNS OF FAILURE IN GROSSLY RESECTED PANCREATIC DUCTAL ADENOCARCINOMA TREATED WITH ADJUVANT IRRADIATION +/- 5-FLUOROURACIL [J].
FOO, ML ;
GUNDERSON, LL ;
NAGORNEY, DM ;
MCLLRATH, DC ;
VANHEERDEN, JA ;
ROBINOW, JS ;
KVOLS, LK ;
GARTON, GR ;
MARTENSON, JA ;
CHA, SS .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 26 (03) :483-489